EGFR and non-small cell lung carcinoma: In patients with EGFR‐mutant NSCLC with BM, epitinib was well tolerable with a promising efficacy. According to the comprehensive assessment on safety and efficacy, 160 mg QD could be the recommended phase 2 dose.